QuidelOrtho Corporation (QDEL)
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago.
Implied Volatility Surging for QuidelOrtho Stock Options
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation strategies outlined.
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
